{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3"},{"groupId":"OG001","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2062"}],"units":"Participants"}],"description":"The incidence of clinical fractures was analyzed.","groups":[{"description":"2.5 mg by mouth (p.o.) once daily","id":"OG000","title":"Letrozole"},{"description":"1 mg p.o. once daily","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","populationDescription":"Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.","reportingStatus":"POSTED","timeFrame":"84 months","title":"Percentage of Participants Who Experienced Clinical Fracture Events","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}